Generation of Rag1 and Rag2 Deficient Mice and Their Application in Tumor Xenograft

doi:10.3969/j.issn.1674-5817.2016.04.004

Abstract

Abstract: Objective To establish recombination-activating genes, Rag1, Rag2 deficiency mouse models and study the possibility as tumor xenograft recipients. Methods The traditional embryonic stem (ES) cell targeting and blastocyst microinjection were performed to develop the Rag1 and Rag2 deficiency mouse models. The flow cytometry assay was conducted to analyze the T/B lymphocyte contents in peripheral blood. The tumorigenicity on different immunodeficiency mouse strains was assessed by exogenous tumor cell transplantation experiment. Results Rag1 and Rag2 deficiency mouse models were established. The T/B lymphocytes of peripheral blood in two strains of homozygous mutant mouse models were significantly reduced compared with those of wild type mice. A549 tumor cells had stronger tumorigenicity in Rag1, Rag2 mutant mice than that in BALB/c nude mice and NOD-SCID mice. Conclusion Rag1, Rag2 deficiency mouse models were successfully developed. Two mouse models display serious immune system defects, which could be used as exogenous tumor transplant recipients to establish tumor model.

Key words: Recombination-activating genes (Rag1 gene), Rag2 gene, Gene defect, Immunodeficiency

CLC Number:

Q95-33

SHEN Ru-ling, SHI Jia-hao, SHENG Zhe-jin, FENG Xiao-long, WU Wen-ting, FEI Jian. Generation of Rag1 and Rag2 Deficient Mice and Their Application in Tumor Xenograft[J]. Laboratory Animal and Comparative Medicine, 2016, 36(4): 263-269.

References

[1] Fugmann SD, Lee AI, Shockett PE, et al.The RAG proteins and V(D)J recombination: complexes, ends, and transposition[J]. Annu Rev Immunol, 2000,18(1):495-527.
[2] Fugmann SD.RAG1 and RAG2 in V(D)J recombination and transposition[J]. Immunol Res, 2001, 23(1):23-39.
[3] Oettinger MA.Activation of V(D)J recombination by RAG1 and RAG2[J]. Trends Genet, 1992, 8(12):413-416.
[4] Schatz DG, Oettinger MA, Baltimore D. The V(D)J recombination activating gene, RAG-1[J]. Cell, 1989, 59(6):1035-1048.
[5] Agrawal A, Schatz DG.RAG1 and RAG2 form a stable postcleavage synaptic complex with DNA containing signal ends in V(D)J recombination[J]. Cell, 1997, 89(1):43-53.
[6] Ru H, Chambers MG, Fu TM, et al.Molecular mechanism of V(D)J recombination from synaptic RAG1-RAG2 complex structures[J]. Cell, 2015, 163(5):1138-1152.
[7] Wilson A, Held W, MacDonald HR. Two waves of recombinase gene expression in developing thymocytes[J]. J Exp Med,1994, 179(5):1355-1360.
[8] Yu W, Nagaoka H, Jankovic M, et al.Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization[J]. Nature,1999, 400(6745):682-687.
[9] Shaw AC, Swat W, Ferrini R, et al.Activated Ras signals developmental progression of recombinase-activating gene (RAG)-deficient pro-B lymphocytes[J]. J Exp Med, 1999,189(1):123-129.
[10] Corneo B, Moshous D, Gungor T, et al.Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome[J]. Blood, 2001, 97(9):2772-2776.
[11] Mombaerts P, Iacomini J, Johnson RS, et al.RAG-1-deficient mice have no mature B and T lymphocytes[J]. Cell, 1992, 68(5):869-877.
[12] Shinkai Y, Rathbun G, Lam KP, et al.RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D) J rearrangement[J]. Cell, 1992, 68(5):855-867.
[13] Bentzien F, Struman I, Martini JF, et al.Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice[J]. Cancer Res, 2001, 61(19):7356-7362.
[14] Shultz LD, Goodwin N, Ishikawa F, et al.Human cancer growth and therapy in NOD/SCID/IL2Rynull(NSG) mice[J]. Cold Spring Harb Protoc, 2014, 7(1):694-708.
[15] Naugler WE, Tarlow BD, Fedorov LM, et al.Fibroblast growth factor signaling controls liver size in mice with humanized livers[J]. Gastroenterology, 2015, 149(3):728-740.
[16] Christa TR, Andre F, Christian F, et al.Composition of intestinal microbiota in immune-deficient mice kept in three different housing conditions[J]. PLoS One, 2014, 9(11): e113406.
[17] Seymour RL, Adams AP, Leal G, et al.A rodent model of Chikungunya virus infection in RAG1-/- mice, with features of persistence, for vaccine safety evaluation[J]. PLoS One, 2015,6(26):e0003800.